You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1 (programmed cell death protein 1)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center, Sun Yat-sen University
Aug 3, 2023

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

Enrolling by invitation
  • Hepatocellular Carcinoma Non-resectable
  • +3 more
  • lenvatinib + sindilimab/carrelizumab
  • TACE
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 23, 2022

Bladder Cancer Trial in Korea, Republic of, Poland, United States (PF-07225570, sasanlimab)

Recruiting
  • Bladder Cancer
  • New York, New York
  • +5 more
Jun 28, 2022

Anti-Programmed Cell Death Protein 1 Immunotherapy in Head and

Recruiting
  • Head and Neck Cancer
  • Strasbourg, France
    Institut de cancérologie Strasbourg Europe
Apr 14, 2022

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 30, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 24, 2023

Recurrent/ Advanced Stage Endometrial Cancer Patients Trial in Guangzhou (Niraparib in Combination With Anti-PD1 Antibody)

Recruiting
  • Recurrent/ Advanced Stage Endometrial Cancer Patients
  • Niraparib in Combination With Anti-PD1 Antibody
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Centre
Aug 20, 2021

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

Recruiting
  • HLA-A2 Positive Cells Present
  • Refractory Melanoma
  • Alpha-type-1 Polarized Dendritic Cells
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 12, 2022

Lichen Planus Trial in Cairo (Skin Biopsy)

Not yet recruiting
  • Lichen Planus
  • Skin Biopsy
  • Cairo, Egypt
    Cairo University
May 14, 2021

EBV Infection Trial in Beijing (PD1 antibody, lenalidomide)

Recruiting
  • EBV Infection
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Jan 4, 2022

NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Capsulized Fecal Microbiota Transplant
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Aug 12, 2021

NSCLC Trial (Drug-eluting beads bronchial arterial chemoembolization, Programmed Cell Death Protein 1 Inhibitor)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Drug-eluting beads bronchial arterial chemoembolization
  • Programmed Cell Death Protein 1 Inhibitor
  • (no location specified)
Feb 17, 2022

EBV Infection Trial in Suzhou (PD-1 mAb)

Recruiting
  • EBV Infection
  • PD-1 monoclonal antibody
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 1, 2021

Plaque, Atherosclerotic, Immune Checkpoint Inhibitors, Programmed Cell Death Protein 1 Inhibitor Trial in Hangzhou (PD-1 immune

Recruiting
  • Plaque, Atherosclerotic
  • +4 more
  • PD-1 immune checkpoint blockades
  • Hangzhou, Zhejiang, China
    The Second Affiliated Hospital of Zhejiang University, School of
Nov 16, 2021

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

Suspended
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 23, 2022

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Hepatocellular Carcinoma Trial in Shanghai (Toripalimab, Sorafenib)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital
Jun 14, 2021

Advanced or Unresectable Melanoma Progressing After PD1 Blockade Trial in Norway, United States (ONCOS-102, Cyclophosphamide,

Completed
Has Results
  • Advanced or Unresectable Melanoma Progressing After PD1 Blockade
  • ONCOS-102
  • +2 more
  • Baltimore, Maryland
  • +3 more
Oct 11, 2021

Melanoma Trial in Worldwide (Relatlimab, Ipilimumab)

Active, not recruiting
  • Melanoma
  • Tucson, Arizona
  • +29 more
Dec 13, 2022

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023